Regen BioPharma Inc (OTCMKTS: RGBP) heading north as biotechnology develops valuable patent portfolio and grants 2 licenses to Oncology Pharma for $ 1.9 million

0


Regen BioPharma Inc (OTCMKTS: RGBP) has moved steadily north in recent trading as speculators return to the action and offer it higher. On Friday, the stock was up 26% to volume of $ 1.9 million. It comes after the company’s CEO David Koos issued a letter to shareholders summarizing some of the recent accomplishments, including the move to the ‘pink stream’ and full compliance, the settlement of the lawsuit with Chemdiv, the growth of the the company’s valuable patent portfolio and the granting of two licenses to Oncology Pharma for which RGBP was paid $ 1,905,000 in cash and securities.

RGBP is one of the most-followed small-cap stocks with a huge investor base and has a long history of big moves that have skyrocketed to 8 cents plus twice in the past 12 months. There are also a lot of buyout rumors on RGBP; according to many investors, it looks like a merger and acquisition is looming with Precigen or another big pharmaceutical company, which would make sense since Precigen’s CEO (PGEN), Helen Sabzevari, sits on the scientific advisory board of RGBP. PGEN trades on the Nasdaq with a market cap of $ 766 million. RGBP is in the same clinical therapeutic niche market of oncology-immunology drug candidate development that Precigen includes the same mRNA vaccine technology, so logically it would make sense for PGEN to directly buy out RGBP or make a merger acquisition and rationale for these are the many valuable patents that RGBP owns and which address huge multi-billion dollar markets.

Regen BioPharma Inc (OTCMKTS: RGBP) “Pink Current” operating out of San Diego, Calif., Is a publicly traded biotechnology company that was founded in 2012 and focuses on the immunology and immunotherapy space. Regen BioPharma focuses on the rapid evolution of new technologies through preclinical and phase I / II clinical trials. Currently, the Company is focused on small molecule therapies for the treatment of cancer and autoimmune diseases. RGBP is also developing products treating blood disorders using small molecules and gene inactivation (DiffronC), treating cancer with cell-based immunotherapy (dCellVax), modulating key molecular processes in cancer stem cells through The Company’s patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and cancer patients treated with chemotherapy / radiotherapy (HemaXellerate). Currently, RGBP has filed 2 New Drug Investigation (IND) applications with the FDA and 3 products in preclinical development based on the new cancer stem cell gene target.

The great story of RGBP is its valuable intellectual property portfolio made up of a large and growing number of patents. Company CEO David Koos has worked hard over the past few months to update all expired patents, a logical step for an acquiring company to take over the patents, then turn around and file a buyout request. FDA IND to immediately place these candidate patents. in their clinical trials pipeline. Recently, RGBP relaunched many existing intellectual property properties that had been deemed abandoned by the United States Patent and Trademark Office and several new patents were issued. CEO David Koos is a very accomplished executive who has worked in the financial markets for 3 decades. He has a doctorate. in sociology and a doctorate in business administration with a specialization in finance.

Last month, RGBP entered into a letter of intent to acquire Canary Oncoceutics, Inc., a new company developing precision in vitro oncology tests using cell technology. The acquisition contemplated by the Non-Binding Letter of Intent is dependent on several factors, including, but not limited to, the completion of due diligence, completion of final negotiations, and execution of a definitive agreement. It is currently envisioned that to complete this acquisition, Regen will need to raise $ 50 million to support the development of the diagnostic platform. Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing.

To check out the inside scoop on RGBP, subscribe to Microcapdaily.com now by entering your email in the box below

RGBP

The cancer genomic test involves analyzing a sample of a cancerous tumor to see how active certain genes are and if they are changed abnormally. The level of activity of these genes affects factors including the likelihood of cancer growing and spreading. By identifying genetic alterations unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target these mutations. However, the list of drugs generated by genomic testing can be quite long, and different patients respond to the same drug differently. Canary Oncoceutics, Inc. is developing tests that take these recommendations and test them on a patient’s tumor in a lab, allowing physicians to narrow down the list of recommendations generated by genomic testing down to drugs or drug combinations. which will work best on that specific topic. patient. “Companion diagnostics in precision oncology is the way to the future of cancer treatment. The global cancer diagnostics market was $ 168 billion in 2020 and is expected to reach $ 280 billion by 20281, ”said David Koos at the time.

On December 30, RGBP CEO David Koos wished shareholders a happy holiday season in a letter to shareholders stating: Company on the verge of bankruptcy. We were behind on invoices, risking losing patent protection on valuable intellectual property and overdue on our SEC filing obligations. Worse yet, we were being sued by Chemdiv, our contract research organization, in a lawsuit seeking damages of $ 1,200,000, which also threatened our ownership rights to valuable intellectual property.

As the year went on, we took on the challenges that lay ahead and overcame them. Regen relaunched many valuable existing intellectual property properties that had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, obtained several new patents, entered into two licensing agreements with unrelated parties and has become up to date with its filing obligations with the SEC. eliminate the risk of the Series A common shares and preferred shares disappearing from the public market.

Getting up to date with our SEC reporting obligations after such a long delinquency has been a significant achievement. Recent changes to SEC Rule 15c2-11 threatened the public trading status of defaulting issuers. I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financial statements. During the quarter ended June 30, 2021, the Company received $ 1,905,000 in cash and securities resulting from two licenses granted in April 2021 to Oncology Pharma, Inc. (“ONPH”).

As the new year dawns, I will work diligently to achieve the goal of concluding additional co-development projects and collaborations that I believe will benefit Regen shareholders and I hope to identify a research organization under contract that will help us move the company’s intellectual property towards clinical trials. .

To learn more about RGBP, subscribe now!

RGBP has moved steadily north in recent trades as speculators move back into the stock and bid higher. The stock was up 26% to volume of $ 1.9 million on Friday. It comes after the company’s CEO David Koos issued a letter to shareholders summarizing some of the recent accomplishments, including the move to the ‘pink stream’ and full compliance, the settlement of the lawsuit with Chemdiv, the growth of the the company’s valuable patent portfolio and the granting of two licenses to Oncology Pharma for which RGBP was paid $ 1,905,000 in cash and securities. RGBP is one of the most-followed small-cap stocks with a huge investor base and has a long history of big moves that have skyrocketed to 8 cents plus twice in the past 12 months. There are also a lot of buyout rumors on RGBP; according to many investors, it looks like a merger and acquisition is looming with Precigen or another big pharmaceutical company, which would make sense since Precigen’s CEO (PGEN), Helen Sabzevari, sits on the scientific advisory board of RGBP. PGEN trades on the Nasdaq with a market cap of $ 766 million. RGBP is in the same clinical therapeutic niche market of oncology-immunology drug candidate development that Precigen includes the same mRNA vaccine technology, so logically it would make sense for PGEN to directly buy out RGBP or make a merger acquisition and rationale for these are the many valuable patents that RGBP owns and which address huge multi-billion dollar markets. We’ll update on RGBP when more details appear, so make sure you’re subscribed to Microcapdaily so you know what’s going on with RGBP.

Disclosure: We do not hold any RGBP positions neither long nor short and we have not been compensated for this item.



Share.

Comments are closed.